Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

Podobne zapisy

• Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
  od: Griffin, M. Pamela, i wsp.
  Wydane: (2017)
• A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
  od: Domachowske, Joseph B, i wsp.
  Wydane: (2017)
• 901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants
  od: Pamela Griffin, Mary, i wsp.
  Wydane: (2019)
• Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
  od: Falloon, Judith, i wsp.
  Wydane: (2017)
• An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
  od: Falloon, Judith, i wsp.
  Wydane: (2017)